Drug Discovery Today
- Print ISSN
- Electronic ISSN
- Impact factor
- Usage rank
- Article count
- Free count
- Free percentage
- PDFs via platforms
- CSA, Rcgp, Proquest, Sciencedirect from 1996, Gale, and Ingenta
Most oral antidiabetic drugs exhibit low oral bioavailability and need to be taken more than once daily owing to short half-lives, resulting in poor patient compliance. There is a necessity for improved drug delivery devices for antidiabetic agents because of the scale of their use and short-com...
• To achieve malaria elimination novel treatments need to block disease transmission. • A new generation of antimalarial candidate drugs holds much promise. ...
• mTOR inhibitors have proven their efficacy and offer renal and antiviral benefits. • Sirolimus and everolimus differ mainly in pharmacokinetic characteristics. ...
• A CNS disease can result in neurological disorders. • Targeting across the blood–brain barrier for CNS therapy is challenging. ...
• Non-antibody scaffold drugs are a promising new class of biologics drugs. • The first candidate scaffolds are now moving into clinical development and practice. ...
• New drug discovery and molecules in clinical development against cancer stem cells. • Surface marker, transcription factors and signal transduction pathways in C...
A growing number of early discovery collaborative agreements are being put in place between large pharma companies and partners in which the rights for assets can reside with a partner, exclusively or jointly. Our corporate screening collection, like many others, was built on the premise that co...
• The first manuscript for more than half of FDA-approved drugs originated in Academia. • Industry has closed the gap in recent years in terms of publishing. ...